Systemic administration of the adenosine A2A agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intake

Pharmacology Biochemistry and Behavior

Volumn 89, Issue 3, 2008, Pages 345-351

  Mingote, Susana ^a   Pereira, Mariana ^a   Farrar, Andrew M ^a   McLaughlin, Peter J ^a   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Basal Ganglia; Motivation; Motor; Operant; Sleep

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE);

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG EFFECT; DRUG POTENCY; DRUG RESEARCH; FEEDING BEHAVIOR; FOOD INTAKE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEDATION;

ADENOSINE; ANIMALS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; HYPNOTICS AND SEDATIVES; MALE; PHENETHYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A;

ANIMALIA; RATTUS;

EID: 40849125472     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.01.006     Document Type: Article

References (68)

1. Andersen M.B., Fuxe K., Werge T., and Gerlach J. The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav Pharmacol 13 (2002) 639-644
2. Arizzi M.N., Cervone K.M., Aberman J.E., Betz A., Liu Q., Lin S., et al. Behavioral effects of inhibition of cannabinoid metabolism: The amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide. Life Sci 74 (2004) 1001-1011
3. Barraco R.A., Martens K.A., Parizon M., and Normile H.J. Adenosine A2a receptors in the nucleus accumbens mediate locomotor depression. Brain Res Bull 31 3-4 (1993) 397-404
4. Blundell J.E. Structure, process and mechanism: case studies in the psychopharmacology of feeding. In: Iversen L.L., Iversen S.D., and Snyder S.H. (Eds). Handbook of Psychopharmacology vol. 19 (1987), Plenum Press, NY 123-182
5. Blundell J.E., and Latham C.J. Characterisation of adjustments to the structure of feeding behaviour following pharmacological treatment: effects of amphetamine and fenfluramine and the antagonism produced by pimozide and methergoline. Pharmacol Biochem Behav 12 (1980) 717-722
6. Burke M., and Sebastian C. Treatment of clozapine sedation. Am J Psychiatr 150 (1993) 1900-1901
7. Cabeza de Vaca S., Kannan P., Pan Y., Jiang N., Sun Y., and Carr K.D. The adenosine A2A receptor agonist, CGS-21680, blocks excessive rearing, acquisition of wheel running, and increases nucleus accumbens CREB phosphorylation in chronically food-restricted rats. Brain Res 1142 (2007) 100-109
8. Carriero D., Aberman J., Lin S.Y., Hill A., Makriyannis A., and Salamone J.D. A detailed characterization of the effects of four cannabinoid agonists on operant lever pressing. Psychopharmacology (Berl) 137 (1998) 147-156
9. Chen J.F., Moratalla R., Impagnatiello F., Grandy D.K., Cuellar B., Rubinstein M., et al. The role of the D2 dopamine receptor (D2R) in A2a adenenosine-receptor (a2ar) mediated behavioral and cellular responses as revealed by A2a and D2 receptor knockout mice. Proc Natl Acad Sci 98 (2001) 1970-1975
10. Chesler E.J., and Salamone J.D. Effects of acute and repeated clozapine injections on cholinomimetic-induced vacuous jaw movements. Pharmacol Biochem Behav 54 3 (1996) 619-624
11. Chuck T.L., McLaughlin P.J., Arizzi-LaFrance M.N., Salamone J.D., and Correa M. Comparison between multiple behavioral effects of peripheral ethanol administration in rats: sedation, ataxia, and bradykinesia. Life Sci 79 2 (2006) 154-161
12. Clifton P.G., Rusk I.N., and Cooper S.J. Effects of dopamine D1 and dopamine D2 antagonists on the free feeding and drinking patterns of rats. Behav Neurosci 105 (1991) 272-281
13. 2A antagonist KF 17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148 (2004) 47-54
14. De Freitas B., and Schwartz G. Effects of caffeine in chronic psychiatric patients. Am J Psychiatr 136 (1979) 1337-1338
15. DeMet E.M., and Chicz-DeMet A. Localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385. Naunyn-Schmiedeberg's Arch Pharmacol 366 (2002) 478-481
16. Farrar A.M., Pereira M., Velasco F., Hockemeyer J., Muller C.E., and Salamone J.D. Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing. Psychopharmacology (Berl) 191 (2007) 579-586
17. Ferré S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) 133 2 (1997) 107-120
18. Ferré S., Freidholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20 (1997) 482-487
19. Ferré S., Popoli P., Gimenez-Llort L., Rimondini R., Müller C.E., Stromberg I., et al. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat Disord 7 (2001) 235-241
20. Ferré S., Ciruela F., Canals M., Marcellino D., Burgueno J., Casado V., et al. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord 10 (2004) 265-271
21. Fibiger H.C., Carter D.A., and Phillips A.G. Decreased intracranial self-stimulation after neuroleptics or 6-hydroxydopamine: evidence for mediation by motor deficits rather than by reduced reward. Psychopharmacology (Berl) 47 (1976) 21-27
22. Gurpegui M., Aguilar M.C., Martínez-Ortega J.M., Diaz F.J., and de Leon J. Caffeine intake in outpatients with schizophrenia. Schizophr Bull 30 (2004) 935-945
23. Hauber W., and Munkel M. Motor depressant effects mediated by dopamine D2 and adenosine A2A receptors in the nucleus accumbens and the caudate-putamen. Eur J Pharmacol 323 2-3 (1997) 127-131
24. Hauber W., Neuscheler P., Nagel J., and Muller C.E. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2a receptors in the caudate putamen of rats. Eur J Neurosci 14 (2001) 1287-1293
25. Hettinger B.D., Lee A., Linden J., and Rosin D.L. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of gabaergic neurons in rat striatum. J Comp Neurol 431 (2001) 331-346
26. Hong Z.Y., Huang Z.L., Qu W.M., Eguchi N., Urade Y., and Hayaishi O. An adenosine A receptor agonist induces sleep by increasing GABA release in the tuberomammillary nucleus to inhibit histaminergic systems in rats. J Neurochem 92 (2005) 1542-1549
27. Hughes J.R., McHugh P., and Holtzman S. Caffeine and schizophrenia. Psychiatr Serv 49 (1998) 1415-1417
28. Ishiwari K., Madson L.J., Farrar A.M., Mingote S.M., Valenta J.P., DiGianvittorio M.D., et al. Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. Behav Brain Res 178 2 (2007) 190-199
29. Jarvis M.F., and Williams M. Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. Eur J Pharmacol 168 (1989) 243-246
30. Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 61 (2003) S32-S38
31. Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Exp Opin Investig Drugs 14 (2005) 729-738
32. Justinova Z., Ferré S., Segal P.N., Antoniou K., Solinas M., Pappas L.A., et al. Involvement of adenosine A1 and A2A receptors in the adenosinergic modulation of the discriminative-stimulus effects of cocaine and methamphetamine in rats. J Pharmacol Exp Ther 307 (2003) 977-986
33. Keppel G. Design and analysis: a researcher's handbook (1991), Prentice-Hall, Englewood Cliffs, NJ
34. Koczapski A., Paredes J., Kogan C., Ledwidge B., and Higenbottam J. Effects of caffeine on behavior of schizophrenic inpatients. Schizophr Bull 15 2 (1989) 339-344
35. Lee M.D., and Clifton P.G. Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol. Pharmacol Biochem Behav 71 (2002) 147-154
36. Ljungberg T. Blockade by neuroleptics of water intake and operant responding in the rat: anhedonia, motor deficit or both?. Pharmacol Biochem Behav 27 (1987) 341-350
37. Ljungberg T. Scopolamine reverses haloperidol-attenuated lever pressing for water but not haloperidol-attenuated water intake in the rat. Pharmacol Biochem Behav 29 (1988) 205-211
38. Ljungberg T. Differential attenuation of water intake and water- rewarded operant responding by repeated administration of haloperidol and SCH 23390 in the rat. Pharmacol Biochem Behav 35 (1990) 111-115
39. Lucas P.B., Pickar D., Kelsoe J., Rapaport M., Pato C., and Hommer D. Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28 (1990) 35-40
40. Mayo K.M., Falkowski W., and Jones C.A. Caffeine: use and effects in long-stay psychiatric patients. Br J Psychiatry 162 (1993) 543-545
41. McLaughlin P.J., Lu D., Winston K.M., Thakur G., Swezey L.A., Makriyannis A., et al. Behavioral effects of the novel cannabinoid full agonist AM411. Pharmacol Biochem Behav 81 1 (2005) 78-88
42. McLaughlin P.J., Winston K.M., Limebeer C.L., Parker L.A., Makriyannis A., and Salamone J.D. The cannabinoid CB1 antagonist AM251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology (Berl) 180 (2005) 286-293
43. Mikkelsen E.J. Caffeine and schizophrenia. J Clin Psychiatry 39 (1978) 732-736
44. Minor T.R., Huang Q., and Foley E.A. Cytokine-purine interactions in behavioral depression in rats. Integr Physiol Behav Sci 38 (2003) 189-202
45. Morelli M., and Pinna A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol Sci 22 (2001) 71-72
46. 2A antagonist KW-6002 on motor and motivational processes in the rat. Psychopharmacology 184 (2006) 46-55
47. Pinna A., Wardas J., Simola N., and Morelli M. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci 77 (2005) 3259-3267
48. Porkka-Heiskanen T., Strecker R.E., and McCarley R.W. Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study. Neuroscience 99 3 (2000) 507-517
49. Rolls E.T., Rolls B.J., Kelly P.H., Shaw S.G., Wood R.J., and Dale R. The relative attenuation of self-stimulation, eating and drinking produced by dopamine-receptor blockade. Psychopharmacologia 38 (1974) 219-230
50. Rusk I.N., and Cooper S.J. Parametric studies of selective D1 and D2 antagonists: effects on appetitive and feeding behavior. Behav Pharmacol 5 (1994) 615-622
51. Safferman A., Lieberman J.A., Kane J.M., Szymansky S., and Kinon B. Update on the clinical efficacy of clozapine. Schizophr Bull 17 (1991) 247-261
52. Salamone J.D., Zigmond M.J., and Stricker E.M. Characterization of the impaired feeding behavior in rats given haloperidol or dopamine-depleting brain lesions. Neuroscience 39 (1990) 17-24
53. Salamone J.D., Kurth P.A., McCullough L.D., Sokolowski J.D., and Cousins M.S. The role of brain dopamine in response initiation: effects of haloperidol and regionally specific dopamine depletions on the local rate of instrumental responding. Brain Res 628 (1993) 218-226
54. Salamone J.D., Mahan K., and Rogers S. Ventrolateral striatal dopamine depletions impair feeding and food handling in rats. Pharmacol Biochem Behav 44 (1993) 605-610
55. Salamone J.D., Cousins M.S., Maio C., Champion M., Turski T., and Kovach J. Different behavioral effects of haloperidol, clozapine and thioridazine in an instrumental lever pressing/feeding procedure. Psychopharmacology (Berl) 125 (1996) 105-112
56. Salamone J.D., Arizzi M., Sandoval M.D., Cervone K.M., and Aberman J.E. Dopamine antagonists alter response allocation but do not suppress appetite for food in rats: contrast between the effects of SKF 83566, raclopride and fenfluramine on a concurrent choice task. Psychopharmacology (Berl) 160 (2002) 371-380
57. Salamone J.D., Font L., Mingote S., Worden L., Stopper C., and Farrar A.M. Forebrain circuitry involved in effort-related functions: intra-accumbens injections of the adenosine A2A agonist CGS 21680 produce an impairment in response allocation similar to that produced by accumbens dopamine depletions. Neuroscience meeting planner (2007), Society for Neuroscience, San Diego, CA Program No. 310.18
58. Satoh S., Matsumura H., and Hayaishi O. Involvement of adenosine A2A receptor in sleep promotion. Eur J Pharmacol 351 (1998) 155-162
59. Scammell T.E., Gerashchenko D.Y., Mochizuki T., McCarthy M.T., Estabrooke I.V., Sears C.A., et al. An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neuroscience 107 4 (2001) 653-663
60. Schiffmann S.N., Jacobs O., and Vanderhaeghen J.J. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 57 (1991) 1062-1067
61. Stenberg D. Neuroanatomy and neurochemistry of sleep. Cell Mol Life Sci 64 (2007) 1187-1204
62. Svenningsson P., Le Moine C., Fisone G., and Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol 59 (1999) 355-396
63. Takahashi R.N., Pamplona F.A., and Prediger R.D. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci 13 (2008) 2614-2632
64. Wang W.F., Ishiwata K., Nonaka H., Ishii S., Kiyosawa M., Shimada J., et al. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. Nucl Med Biol 27 (2000) 541-546
65. 2A receptors in the treatment of schizophrenia. Fontiers Biosci (in press).
66. Wardas J., Konieczny J., and Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41 (2001) 160-171
67. Wardas J., Konieczny J., and Pietraszek M. Influence of CGS 21680, a selective adenosine A(2A) agonist, on the phencyclidine-induced sensorimotor gating deficit and motor behaviour in rats. Psychopharmacology (Berl) 168 (2003) 299-306
68. Weerts E.M., and Griffiths R.R. The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. Psychopharmacology 168 (2003) 155-163